🎄Holiday Notice: Shipping for temperature-sensitive medications (Ozempic, Mounjaro, etc.) is paused. Service resumes Monday, Dec 29.
Generic Semaglutide Now Available!
We Ship To The U.S. Only
Call Toll Free:
10% OFF
On Your First Order
Copy Code
MYRX10
Navigating the complex landscape of type 2 diabetes treatments can often be overwhelming for patients and healthcare professionals alike. Medical researchers are continuously developing innovative solutions and refined strategies to manage and reduce the effects of diabetes. Oral medications are central to this ongoing evolution in medicine, and they have come to the forefront as pivotal tools for management of diabetes.
Among these, Jardiance® and Farxiga® stand out, consistently drawing attention within both the medical community and patient circles. These drugs, classified under the umbrella of SGLT2 inhibitors, represent progress in diabetes care, offering a unique mode of action distinct from traditional antidiabetic agents. Jardiance® is formulated with empagliflozin, while Farxiga® contains dapagliflozin.
Both Jardiance® and Farxiga® serve the same overarching objective: the regulation of blood sugar levels in people with type 2 diabetes. Yet, as with all medical treatments, it’s important to look deeper and understand the differences and shared characteristics between these drugs. While they share a common classification, each drug brings its distinctive formulation and variation in effects, underscoring the importance of informed decision-making when choosing medication.
Let’s explore the specific characteristics of Jardiance® and Farxiga®, identify their core ingredients, learn how they were developed, and compare their mechanisms of action. Through this comparison, we will better understand the efficacy of these drugs, their place in diabetes management, and the potential benefits they have beyond blood sugar regulation.
10% OFF
On Your First Order
Copy Code
MYRX10
Empagliflozin functions as a sodium-glucose co-transporter 2 (SGLT2) inhibitor, purposefully designed to address high blood sugar linked to type 2 diabetes.
Empagliflozin emerged from research that aimed to find enhanced and safer diabetes treatments. The strategy involved targeting SGLT2 to decrease elevated blood sugar by enabling increased glucose excretion through the urine. A molecule was designed to inhibit the protein regulating glucose transport in the kidneys, and this molecule was empagliflozin
By targeting SGLT2 in the kidneys, which plays a pivotal role in glucose reabsorption, empagliflozin obstructs glucose transport and leads to excess glucose expulsion through urine and stabilized blood sugar levels. Besides glucose regulation, empagliflozin aids in calorie loss due to glucose excretion, potentially contributing to slight weight reduction. This medication can also reduce the amount of insulin needed for glucose metabolism without directly influencing insulin levels.
As for dapagliflozin, its function and purpose mirror that of empagliflozin, therefore deserving equal attention in diabetes management. Dapagliflozin, like its counterpart empagliflozin, plays an instrumental role in the management of type 2 diabetes.
Dapagliflozin operates in the same category of drugs, the SGLT2 inhibitors, as empagliflozin. Its development was driven by the urgent need to manage high blood sugar levels seen in people with type 2 diabetes.
The path to discovery of dapagliflozin paralleled that of empagliflozin and was rooted in the urgency to develop better type 2 diabetes treatments. The formulation of dapagliflozin came from precise drug design and rigorous preclinical evaluations. Researchers sought a compound that could specifically disrupt the action of the SGLT2 protein and block the transport of glucose from the kidneys back into the circulatory system. This mission led to
dapagliflozin.
Dapagliflozin mirrors empagliflozin in how it works. It focuses on the predominance of SGLT2 in the proximal tubules of the kidneys, given the role of SGLT2 in glucose reabsorption. This makes SGLT2 a potent target for therapeutic interventions.
The medicinal effects of dapagliflozin align closely with empagliflozin and include:
Both Jardiance® (empagliflozin) and Farxiga® (dapagliflozin) stand out in the therapeutic landscape due to their ability to regulate blood sugar by modulating glucose reabsorption in the kidneys. Plus, their benefits are not confined to glycemic control alone. Research trials have indicated that both drugs might have additional cardiovascular and renal advantages, further supporting their position as breakthroughs in addressing type 2 diabetes and its associated complica
Jardiance® is endorsed for two primary applications:
Jardiance® is predominantly recommended for adults for regulation of type 2 diabetes. Its mechanism allows greater control over glycemic levels by reducing elevated blood sugar levels.
Jardiance® plays a pivotal role in reducing the chances of critical cardiovascular complications, such as heart attacks and cerebral strokes, in people with type 2 diabetes. It also reduces the likelihood of progression of cardiovascular issues or associated incidents. Jardiance® promotes these benefits through:
Farxiga® has been endorsed for various clinical uses, including:
Farxiga® is recommended for the control of type 2 diabetes in adults. It can be administered as a standalone medication or in combination with other diabetes treatments.
Farxiga® (dapagliflozin) is used to decrease the likelihood of heart failure hospitalizations in adults diagnosed with type 2 diabetes and recognized cardiovascular issues. It does this through several vital pathways:
Both Jardiance® and Farxiga® come in pill form and are meant for oral consumption.
The suggested initial dose for Jardiance® is 10 mg daily. If there’s a need for further blood sugar regulation, the dose can be raised to 25 mg daily.
Typically, Farxiga® is administered at a dose of 5 mg daily. If greater blood sugar management is required, the dosage can be enhanced to 10 mg daily. The 10 mg dosage is also preferred for people diagnosed with
cardiovascular ailments or for those having type 2 diabetes accompanied by several cardiovascular risk elements.
Both Jardiance® and Farxiga® fall under the same drug category, leading to some overlapping side effects. However, each medication has its specific side effects as well.
Infections in the urinary tract
Elevated urine output
Excessive thirst
Reduced blood pressure
Both Jardiance® and Farxiga® fall under the same drug category, leading to some overlapping side effects. However, each medication has its specific side effects as well.
Distinct Adverse Reaction for Jardiance®: Frequent urination
Distinct Adverse Reactions for Farxiga®: Inflammation affecting the nasal passage and throat, discomfort in the back region and skin disturbances (rashes, itchiness).
The landscape of type 2 diabetes treatments is continually evolving, and among the pivotal tools in diabetes management are oral medications like Jardiance® and Farxiga®. These SGLT2 inhibitors play a crucial role in regulating blood sugar levels in people with type 2 diabetes. While both medications share a common classification, they have distinct formulations and mechanisms of action.
Jardiance®, with empagliflozin as its primary ingredient, targets glucose reabsorption in the kidneys, leading to increased glucose excretion through urine, stabilized blood sugar levels, and potential weight reduction. It also offers cardiovascular and renal benefits.
Jardiance® (Empagliflozin):
Farxiga®, containing dapagliflozin, operates similarly, reducing blood sugar and offering cardiovascular advantages, including lowering the risk of heart failure hospitalizations.
Farxiga® (Dapagliflozin):
Both Jardiance® and Farxiga® are taken orally and exhibit shared adverse reactions like genital fungal infections, urinary infections, augmented urination, dehydration, and hypotension. Jardiance® is associated with more frequent urination, while Farxiga® might induce symptoms like upper respiratory tract inflammation, dorsalgia, and dermal reactions.
These medications represent significant strides in managing type 2 diabetes, not only in glycemic control but also in potential ancillary benefits for the cardiovascular system. It’s essential for people managing type 2 diabetes to work closely with their healthcare providers to determine the most appropriate treatment plan tailored to their specific needs and goals.
Written & Reviewed By
The MyRx Team
The MyRx Outlet team is a dedicated group of healthcare professionals and pharmacists dedicated to delivering up-to-date and accurate information on medications and key healthcare topics. With years of experience in the healthcare field, our team is passionate about supporting individuals in reaching their health and wellness goals through our articles.
The information provided here is for educational purposes only and is not intended to serve as medical advice, diagnosis, or treatment recommendations. It should not be taken as an endorsement of any specific medication or treatment. Individual health conditions and responses to treatment can vary greatly; therefore, this information should not be seen as a guarantee of safety, suitability, or effectiveness for any particular individual. Always consult with a healthcare professional for personalized medical advice and before making any decisions regarding your health or treatment plans.
Learn what compounded tirzepatide is, how it differs from Mounjaro and Zepbound, and what to know about its safety, cost, and FDA regulations.
Learn what compounded tirzepatide is, how it differs from Mounjaro and Zepbound, and what to know about its safety, cost, and FDA regulations.
Learn how to store Wegovy safely. Find out when to refrigerate, how long it lasts at room temperature, and tips for traveling with your medication.
Share:
